ascopubs.org

VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth ...

TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic ...
World Bank

Future of Government: Case Studies

The aim of the case studies below is to help in think through some past experiences of governments and reform, as governments, countries, and people face the future. The examples discussed are not ...
ascopubs.org

A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair ...

Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in advanced solid tumors. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a full ...
Nature

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...